Sensex
83,878.17 profit arw 301.93 (0.36%)
Nifty
25,790.25 profit arw 106.95 (0.42%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 01-Jan-2026
Hot Pursuit
01-Jan-2026     11:57

Dr Reddy's Swiss subsidiary gets USFDA CRL for biosimilar AVT03

AVT03 is a proposed biosimilar to Amgen's Prolia and Xgeva and has been developed by Alvotech hf. According to the company, the CRL pertains to observations made by the US Food and Drug Administration (USFDA) during a pre-licence inspection of Alvotech's manufacturing facility in Reykjavik, Iceland.

Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company's consolidated net profit jumped 7.3% to Rs 1,347.10 crore on a 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25.

The counter slipped 1.66% to Rs 1,250 on the BSE.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

83,878.17 301.93 (0.36%)

Nifty

25,790.25 106.95 (0.42%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

26,608.48 376.68(1.44%)